SIRT3 and T-cell non-Hodgkin lymphoma: These results uncover unknown regulation of SIRT3 by the SIN3 complex via SAP18, and identify A671 as a potent inhibitor for the treatment of erythroleukemia, T-cell lymphoma, and possibly other malignancies.